Skip to main content
Top
Published in: BMC Pregnancy and Childbirth 1/2020

Open Access 01-12-2020 | Fertility | Research article

Fertility treatment and oral contraceptive discontinuation for identification of pregnancy planning in routinely collected health data – an application to analgesic and antibiotic utilisation

Authors: Sarah Hjorth, Mollie Wood, Fatima Tauqeer, Hedvig Nordeng

Published in: BMC Pregnancy and Childbirth | Issue 1/2020

Login to get access

Abstract

Background

Women with unplanned pregnancies use folic acid less frequently, and more often use potentially teratogenic medications in the first trimester. Yet most studies based on routinely collected data lack information on pregnancy planning. Further, only pregnancies proceeding beyond a certain gestational age appear in routinely collected data, creating the possibility for collider-stratification bias. If pregnancy intention could be identified, pregnancies could be ascertained earlier. This study aimed to investigate fertility treatment and discontinuation of oral contraception (OC) as proxies for pregnancy planning by describing variations in patterns of prescription fills for antibiotics and analgesics during the peri-pregnancy period by these proxies of pregnancy intention.

Methods

Fertility treatment with clomiphene and discontinuation of OC were identified in the Norwegian Prescription Database (NorPD) and linked with data from the Medical Birth Registry of Norway for the years 2006 to 2017. Filled prescriptions for antibiotics and analgesics from NorPD were displayed for women on fertility treatment, women who discontinued OC before pregnancy, and women who discontinued during pregnancy.

Results

Of 172,585 included pregnancies, fertility treatment was identified in 19,449, and OC discontinuation before or during pregnancy in 153,136. Women who discontinued OC during pregnancy were less likely to use preconception folic acid (25.4%) than women who discontinued before pregnancy (32.9%), and women on fertility treatment (51.0%). Proportions of first trimester prescription fills were 4.9% (analgesics) and 12.8% (antibiotics) for women who discontinued OC during pregnancy, compared to 4.0 and 11.4% in women who discontinued OC before pregnancy, and 4.7 and 11.0% in women on fertility treatment.

Conclusions

There were no substantial differences in patterns of prescription fills for analgesics and antibiotics before or during pregnancy by fertility treatment and OC discontinuation. This suggests that there were few differences in medication use between women with planned and unplanned pregnancies, or that fertility treatment and timing of OC discontinuation from routinely collected health data cannot stand alone in the identification of unplanned pregnancies. A narrower definition of OC discontinuation during pregnancy seemed to be a better proxy, but this should be confirmed in other studies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bearak J, Popinchalk A, Alkema L, Sedgh G. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health. 2018;6(4):e380–9.CrossRef Bearak J, Popinchalk A, Alkema L, Sedgh G. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health. 2018;6(4):e380–9.CrossRef
2.
go back to reference Stern J, Salih Joelsson L, Tydén T, Berglund A, Ekstrand M, Hegaard H, et al. Is pregnancy planning associated with background characteristics and pregnancy-planning behavior? Acta Obstet Gynecol Scand. 2016;95(2):182–9.CrossRef Stern J, Salih Joelsson L, Tydén T, Berglund A, Ekstrand M, Hegaard H, et al. Is pregnancy planning associated with background characteristics and pregnancy-planning behavior? Acta Obstet Gynecol Scand. 2016;95(2):182–9.CrossRef
3.
go back to reference Hill B, Kothe EJ, Currie S, Danby M, Lang AY, Bailey C, et al. A systematic mapping review of the associations between pregnancy intentions and health-related lifestyle behaviours or psychological wellbeing. Prev Med Rep. 2019;14:100869.CrossRef Hill B, Kothe EJ, Currie S, Danby M, Lang AY, Bailey C, et al. A systematic mapping review of the associations between pregnancy intentions and health-related lifestyle behaviours or psychological wellbeing. Prev Med Rep. 2019;14:100869.CrossRef
4.
go back to reference Stephenson J, Heslehurst N, Hall J, Schoenaker DAJM, Hutchinson J, Cade JE, et al. Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health. Lancet. 2018;391(10132):1830–41.CrossRef Stephenson J, Heslehurst N, Hall J, Schoenaker DAJM, Hutchinson J, Cade JE, et al. Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health. Lancet. 2018;391(10132):1830–41.CrossRef
5.
go back to reference Cleary BJ, Butt H, Strawbridge JD, Gallagher PJ, Fahey T, Murphy DJ. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf. 2010;19(4):408–17.CrossRef Cleary BJ, Butt H, Strawbridge JD, Gallagher PJ, Fahey T, Murphy DJ. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf. 2010;19(4):408–17.CrossRef
6.
go back to reference Palmsten K, Hernández-Díaz S, Chambers CD, Mogun H, Lai S, Gilmer TP, et al. The Most commonly dispensed prescription medications among pregnant women enrolled in the U.S. Medicaid program. Obstet Gynecol. 2015;126(3):465–73.CrossRef Palmsten K, Hernández-Díaz S, Chambers CD, Mogun H, Lai S, Gilmer TP, et al. The Most commonly dispensed prescription medications among pregnant women enrolled in the U.S. Medicaid program. Obstet Gynecol. 2015;126(3):465–73.CrossRef
7.
go back to reference Engeland A, Bjørge T, Klungsøyr K, Hjellvik V, Skurtveit S, Furu K. Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015. Pharmacoepidemiol Drug Saf. 2018;27(9):995–1004.CrossRef Engeland A, Bjørge T, Klungsøyr K, Hjellvik V, Skurtveit S, Furu K. Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015. Pharmacoepidemiol Drug Saf. 2018;27(9):995–1004.CrossRef
9.
go back to reference Liew Z, Olsen J, Cui X, Ritz B, Arah OA. Bias from conditioning on live birth in pregnancy cohorts: an illustration based on neurodevelopment in children after prenatal exposure to organic pollutants. Int J Epidemiol. 2015;44(1):345–54.CrossRef Liew Z, Olsen J, Cui X, Ritz B, Arah OA. Bias from conditioning on live birth in pregnancy cohorts: an illustration based on neurodevelopment in children after prenatal exposure to organic pollutants. Int J Epidemiol. 2015;44(1):345–54.CrossRef
10.
go back to reference Riskin-Mashiah S, Auslender R. Periconceptional folic acid and teratogenic drug use in women undergoing fertility treatments. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet. 2012;25(10):1899–903. Riskin-Mashiah S, Auslender R. Periconceptional folic acid and teratogenic drug use in women undergoing fertility treatments. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet. 2012;25(10):1899–903.
12.
go back to reference Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mårdby AC, Moretti ME, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open. 2014;4(2):e004365.CrossRef Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mårdby AC, Moretti ME, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open. 2014;4(2):e004365.CrossRef
13.
go back to reference Ersbøll AS, Hedegaard M, Damm P, Johansen M, Tabor A, Hegaard HK. Changes in the pattern of paracetamol use in the periconception period in a Danish cohort. Acta Obstet Gynecol Scand. 2015;94(8):898–903.CrossRef Ersbøll AS, Hedegaard M, Damm P, Johansen M, Tabor A, Hegaard HK. Changes in the pattern of paracetamol use in the periconception period in a Danish cohort. Acta Obstet Gynecol Scand. 2015;94(8):898–903.CrossRef
14.
go back to reference Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for Pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106(2):86–94.CrossRef Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for Pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106(2):86–94.CrossRef
16.
go back to reference Langhoff-Roos J, Krebs L, Klungsøyr K, Bjarnadottir RI, Källén K, Tapper A-M, et al. The Nordic medical birth registers - a potential goldmine for clinical research. Acta Obstet Gynecol Scand. 2014;93(2):132–7.CrossRef Langhoff-Roos J, Krebs L, Klungsøyr K, Bjarnadottir RI, Källén K, Tapper A-M, et al. The Nordic medical birth registers - a potential goldmine for clinical research. Acta Obstet Gynecol Scand. 2014;93(2):132–7.CrossRef
17.
go back to reference Irgens LM. Medical birth registry--an essential resource in perinatal medical research. Tidsskr Den Nor Laegeforening Tidsskr Prakt Med Ny Raekke. 2002;122(26):2546–9. Irgens LM. Medical birth registry--an essential resource in perinatal medical research. Tidsskr Den Nor Laegeforening Tidsskr Prakt Med Ny Raekke. 2002;122(26):2546–9.
18.
go back to reference Kjøtrød S, Hentemann MA, Johansen MS, Hausken J, Veholmen M, Birkeland S. Infertilitet. In: Veileder i gynekologi. Norsk gynekologisk forening; 2015. Kjøtrød S, Hentemann MA, Johansen MS, Hausken J, Veholmen M, Birkeland S. Infertilitet. In: Veileder i gynekologi. Norsk gynekologisk forening; 2015.
19.
go back to reference Hemminki E, Klemetti R, Rinta-Paavola M, Martikainen J. Identifying exposures of in vitro fertilization from drug reimbursement files: a case study from Finland. Med Inform Internet Med. 2003;28(4):279–89.CrossRef Hemminki E, Klemetti R, Rinta-Paavola M, Martikainen J. Identifying exposures of in vitro fertilization from drug reimbursement files: a case study from Finland. Med Inform Internet Med. 2003;28(4):279–89.CrossRef
20.
go back to reference Triebwasser JE, Higgins S, Secura GM, Zhao Q, Peipert JF. Pharmacy claims data versus patient self-report to measure contraceptive method continuation. Contraception. 2015;92(1):26–30.CrossRef Triebwasser JE, Higgins S, Secura GM, Zhao Q, Peipert JF. Pharmacy claims data versus patient self-report to measure contraceptive method continuation. Contraception. 2015;92(1):26–30.CrossRef
21.
go back to reference Vollset SE, Gjessing HK, Tandberg A, Rønning T, Irgens LM, Baste V, et al. Folate supplementation and twin pregnancies. Epidemiol Camb Mass. 2005;16(2):201–5.CrossRef Vollset SE, Gjessing HK, Tandberg A, Rønning T, Irgens LM, Baste V, et al. Folate supplementation and twin pregnancies. Epidemiol Camb Mass. 2005;16(2):201–5.CrossRef
22.
go back to reference Nordeng H, Jettestad M, Sitras V. Legemiddelbruk i svangerskapet og ammeperioden. In: Veileder i fødselshjelp. Fredrikstad, Hammerfest, Bergen, Oslo: Norsk gynekologisk forening; 2020. Nordeng H, Jettestad M, Sitras V. Legemiddelbruk i svangerskapet og ammeperioden. In: Veileder i fødselshjelp. Fredrikstad, Hammerfest, Bergen, Oslo: Norsk gynekologisk forening; 2020.
23.
go back to reference Nordeng S, Nordeng H, Høye S. Bruk av antibiotika i svangerskapet. Tidsskr Den Nor Legeforening. 2016;136(4):317–21.CrossRef Nordeng S, Nordeng H, Høye S. Bruk av antibiotika i svangerskapet. Tidsskr Den Nor Legeforening. 2016;136(4):317–21.CrossRef
24.
go back to reference Bateman BT, Mhyre JM, Hernandez-Diaz S, Huybrechts KF, Fischer MA, Creanga AA, et al. Development of a comorbidity index for use in obstetric patients. Obstet Gynecol. 2013;122(5):957–65.CrossRef Bateman BT, Mhyre JM, Hernandez-Diaz S, Huybrechts KF, Fischer MA, Creanga AA, et al. Development of a comorbidity index for use in obstetric patients. Obstet Gynecol. 2013;122(5):957–65.CrossRef
25.
go back to reference Andrade SE, Bérard A, Nordeng HME, Wood ME, van Gelder MMHJ, Toh S. Administrative claims data versus augmented pregnancy data for the study of pharmaceutical treatments in pregnancy. Curr Epidemiol Rep. 2017;4(2):106–16.CrossRef Andrade SE, Bérard A, Nordeng HME, Wood ME, van Gelder MMHJ, Toh S. Administrative claims data versus augmented pregnancy data for the study of pharmaceutical treatments in pregnancy. Curr Epidemiol Rep. 2017;4(2):106–16.CrossRef
26.
go back to reference Koopmans PC, Bos JHJ, de Jong van den Berg LTW. Are antibiotics related to oral combination contraceptive failures in the Netherlands? A case-crossover study. Pharmacoepidemiol Drug Saf. 2012;21(8):865–71.CrossRef Koopmans PC, Bos JHJ, de Jong van den Berg LTW. Are antibiotics related to oral combination contraceptive failures in the Netherlands? A case-crossover study. Pharmacoepidemiol Drug Saf. 2012;21(8):865–71.CrossRef
27.
go back to reference Toh S, Mitchell AA, Anderka M, de Jong-van den Berg LTW, Hernández-Díaz S. National Birth Defects Prevention Study. Antibiotics and oral contraceptive failure - a case-crossover study. Contraception. 2011;83(5):418–25.CrossRef Toh S, Mitchell AA, Anderka M, de Jong-van den Berg LTW, Hernández-Díaz S. National Birth Defects Prevention Study. Antibiotics and oral contraceptive failure - a case-crossover study. Contraception. 2011;83(5):418–25.CrossRef
28.
go back to reference Archer JSM, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol. 2002;46(6):917–23.CrossRef Archer JSM, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol. 2002;46(6):917–23.CrossRef
29.
go back to reference Nilsen RM, Vollset SE, Gjessing HK, Magnus P, Meltzer HM, Haugen M, et al. Patterns and predictors of folic acid supplement use among pregnant women: the Norwegian mother and child cohort study. Am J Clin Nutr. 2006;84(5):1134–41.CrossRef Nilsen RM, Vollset SE, Gjessing HK, Magnus P, Meltzer HM, Haugen M, et al. Patterns and predictors of folic acid supplement use among pregnant women: the Norwegian mother and child cohort study. Am J Clin Nutr. 2006;84(5):1134–41.CrossRef
30.
go back to reference Serfaty D. Update on the contraceptive contraindications. J Gynecol Obstet Hum Reprod. 2019;48(5):297–307.CrossRef Serfaty D. Update on the contraceptive contraindications. J Gynecol Obstet Hum Reprod. 2019;48(5):297–307.CrossRef
31.
go back to reference Strøm-Roum EM, Lid J, Eskild A. Use of contraception among women who request first trimester pregnancy termination in Norway. Contraception. 2016;94(2):181–6.CrossRef Strøm-Roum EM, Lid J, Eskild A. Use of contraception among women who request first trimester pregnancy termination in Norway. Contraception. 2016;94(2):181–6.CrossRef
32.
go back to reference Lindh I, Skjeldestad FE, Gemzell-Danielsson K, Heikinheimo O, Hognert H, Milsom I, et al. Contraceptive use in the Nordic countries. Acta Obstet Gynecol Scand. 2017;96(1):19–28.CrossRef Lindh I, Skjeldestad FE, Gemzell-Danielsson K, Heikinheimo O, Hognert H, Milsom I, et al. Contraceptive use in the Nordic countries. Acta Obstet Gynecol Scand. 2017;96(1):19–28.CrossRef
Metadata
Title
Fertility treatment and oral contraceptive discontinuation for identification of pregnancy planning in routinely collected health data – an application to analgesic and antibiotic utilisation
Authors
Sarah Hjorth
Mollie Wood
Fatima Tauqeer
Hedvig Nordeng
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Pregnancy and Childbirth / Issue 1/2020
Electronic ISSN: 1471-2393
DOI
https://doi.org/10.1186/s12884-020-03435-4

Other articles of this Issue 1/2020

BMC Pregnancy and Childbirth 1/2020 Go to the issue